Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Alzheimers Awareness topic
No spam. Unsubscribe anytime.
Sponsors reintroduce bill to coordinate Alzheimer's public outreach, stress early detection
Summary
Representatives Baker and Fuchs reintroduced HB254 to require the Ohio Department of Health to coordinate with the Department of Aging, the Commission on Minority Health and community groups to boost public and clinician awareness of Alzheimer's and dementia, with a focus on risk reduction and early detection.
Get email alerts on the Alzheimers Awareness topic
No spam. Unsubscribe anytime.
Representatives Baker and Fuchs told the House Health Committee they reintroduced House Bill 254 to coordinate state and community efforts to educate Ohioans about Alzheimer's disease and other dementias, emphasizing risk reduction and the importance of early detection.
"Over 230,000 Ohioans are living with Alzheimer's disease and over 450,000 family members are providing care to them," Representative Baker said, noting that a substantial share of people with early symptoms had not discussed them with health-care providers. Baker told the committee the bill aims to raise awareness so families notice early signs and seek timely diagnosis and treatment that can slow cognitive decline.
Representative Fuchs, the bill's joint sponsor, said the legislation would task the Ohio Department of Health to coordinate with the Department of Aging, the Commission on Minority Health and community organizations to incorporate early warning signs, risk-reduction guidance, evidence-based assessment tools and the role of annual wellness visits into public outreach for both family members and clinicians.
Committee members asked about curriculum content and whether outreach would include causes of cognitive decline; sponsors said HB254 focuses on proven risk-reduction behaviors (healthy diet, sleep, physical and cognitive activity) while also informing clinicians so they remain current on diagnostics and treatments. Representatives noted recent developments such as FDA-approved blood tests and new infusion treatments that make early diagnosis more consequential.
The chair closed the first hearing and invited additional proponents to provide testimony in later sessions.
